LifeSplice was awarded an NIH Phase I/Phase II SBIR Fast-Track CREATE grant. The $670K Phase I grant foc...
Directing alternative splicing to conquer disease
NIH Grant Awarded ($340K) for Initial Drug Development of a Novel Alzheimer’s Disease Treatment.
LifeSplice was awarded an NIH R21 grant for the initial development of SMOs to alter the expression of RA...
AMPA GluA1-flip targeted oligonucleotide therapy paper published in PLOS One Journal
LifeSplice Pharma is pleased to announce the publication of the article "AMPA GluA1-flip targeted oligonucleotide therapy reduces...